FDA’s Drug Price Push in Biosimilar Plan Hinges on Other Reforms

The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will ...
CBS News

FDA's plan to boost cheaper copycat drugs could stall at the patent office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...
The Spokesman-Review

FDA’s plan to boost biosimilar drugs could stall at the patent office

News Nation/World FDA’s plan to boost biosimilar drugs could stall at the patent office Nov. 28, 2025 Updated Sat., Nov. 29, 2025 at 9:37 p.m. Food and Drug Administration (FDA) Commissioner Dr. Marty ...
Medical Xpress

FDA's plan to boost biosimilar drugs could stall at the patent office

These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the agency's plan, which he said would halve the time and money needed to get what are called "biosimilar" drugs to ...